3 best performing ASX shares in the week of 4 April 2022

Marc Kennis Marc Kennis, April 11, 2022

Best performing ASX shares

The three best performing ASX shares in the week of 4 April 2022 were Legacy Iron Ore (ASX:LCY), up 60%, Hawsons Iron (ASX:HIO), up 46.4%, and Toro Energy (ASX:TOE), up 45%

 

GET A 30-DAY FREE TRIAL TO STOCKS DOWN UNDER

 
1. Legacy Iron Ore (ASX:LCY)

Industry: Resources

Legacy Iron Ore Limited (LCY) is a Western Australian-based company, focused on iron ore, base metals, tungsten and gold development and mineral discovery.

Market Cap: $205m

12 month high / low: $0.012 – $0.042

 

Legacy Iron Ore

 

 

2. Hawsons Iron (ASX:HIO)

Industry: Resources

Hawsons Iron Ltd (HIO, formerly Carpentaria Resources Ltd) is a mineral exploration company. HIO is currently focused on developing its flagship Hawsons Iron Project near Broken Hill, NSW into a premium producer of high-quality iron ore products for the global steel industry.

Market Cap: $293M

12 month high / low: $0.035 – $0.435

 

Hawson Iron

 

 

3. Toro Energy (ASX:TOE)

Industry: Energy

Toro Energy Limited (TOE) is an ASX listed uranium development and exploration company with projects in WA. Current focus of the company is on advancement and development of Wiluna Uranium Project and initiate exploration of Yandal gold project.

Market Cap: $113m

12 month high / low: $0.012 – $0.058

 

Toro Energy

 

 

Learn more about ASX-listed stocks with
Stocks Down Under!

 

Subscribe to Stocks Down Under today!

 

GET A 30-DAY FREE TRIAL

 

No credit card needed and the trial expires automatically.

 

 

Blog Categories

Get Our Top 5 ASX Stocks for FY25

Recent Posts

gold stocks

Can Gold Hit $4,000 in 2025? These 5 ASX Stocks Could Soar if It Does

In our view, the question isn’t just whether gold can hit $4,000 an ounce in 2025; it’s about what happens…

Qantas Board Shake-Up

Qantas Board Shake-Up: Is Investor Pressure Finally Taking Effect?

Qantas Airways, Australia’s flagship airline, has long been a symbol of national pride, maintaining a central position in the country’s…

Orthocell

Orthocell (ASX:OCC): All systems go for a US market roll out of its flagship Remplir nerve repair product

Orthocell (ASX:OCC) is the latest ASX biotech to obtain FDA approval. Its nerve repair product Remplir was already approved in…